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Abstract
The cytochromes P450 (CYPs) are a group of enzymes that are primarily 
responsible for oxidative drug biotransformation in people. CYP2B6, which 
metabolizes numerous drugs including bupropion, propofol and other drug 
shows great variability in rates of drug oxidation between individuals. In this 
chapter we discuss the contribution of selected genetic and environmental factors 
to this variability. Several studies identified and quantified the most common 
CYP2B6 mRNA splice such as deletion of exons 4 to 6 and of exon 4 which were 
significantly and negatively correlated with CYP2B6 protein and enzyme activity. 
CYP2B6 gene expression is highly inducible by phenobarbital. Alcohol ingestion 
has been associated with increased CYP2B6 levels this involves the constitutive 
androstane receptor (CAR) and/or the pregnane X receptor (PXR). CYP2B7 is 
considered a pseudogene because of the presence of a single premature stop codon 
(TGA) in exon 7. In 10 out of 24 African-Americans (but none out of 48 European-
Americans) there is a single nucleotide polymorphism that results in an arginine 
codon instead of a stop codon (X378R). The results of these studies identify certain 
CYP2B6 genetic polymorphisms, mRNA splicing variants, and alcohol ingestion as 
significant factors that determine interindividual variability of CYP2B-mediated 
oxidation of drugs in people.
Keywords: Cytochromes, cytochromes P450, CYP2B6, CYP2B6 activity,  
drug oxidation
1. Introduction
Large interindividual variability in drug response is more of a rule than an 
exception. In fact, among patients treated with the same dose of drug, the response 
varies widely from no response at all to severe side effects. Many factors contribute 
to this variability, and apart from the role of non-pharmacological aspects, such as 
psychological and social issues, it mainly results from the interaction of genetic, 
pathophysiological and environmental factors that lead to interindividual differ-
ences in drug pharmacokinetics and pharmocodynamics. Since the discovery of the 
debrisoquine/sparteine hydroxylation polymorphism in 1970, research has expanded 
in the study of the interaction between environmental and genetic factors control-
ling the rate of drug metabolism. Currently, it is well known that cytochrome P450 
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(CYP) mediated drug metabolism shows large variability, leading to large differences 
in steady-state plasma concentrations of drugs. This variability is due to interaction 
of genetics and environmental factors. In addition, concomitant drug administration 
influences the variabilty of drug response. The main objective of the work described 
in this thesis dissertation was to study the role of genetic and environmental factors 
in determining interindividual variability of the CYP2B subfamily.
1.1 CYP enzymes
The cytochrome P450 (CYP) superfamily of enzymes plays a predominant role 
in the phase I metabolism of xenobiotics, environmental chemicals and endogenous 
compounds. An overview of the the most common reaction catalyzed by CYP is as 
follows:
 R H O2 NADPH H R OH NADP H2O− + + + +→ − + + +  (1)
The CYP enzymes are classified into families and subfamilies based on their 
amino acid sequence similarity. The CYP nomenclature is as follows: “P” stands for 
“pigment”, “cyto” means “hollow vesicle”, and “chrome” means “color”. “450” is part 
of the name since the reduced enzyme absorbs light at 450 nm when bound to carbon 
monoxide. ‘CYP’ represents the CYP family. Members of the same family represented 
by a number (e.g. CYP2) share at least 40% identical with respect to their amino acid 
sequences. If the sequences are 40–55% identical, the enzymes belong to the same 
subfamily, indicated by an additional letter (e.g. CYP2B). Finally, each individual 
enzyme is represented by an Arabic numeral (e.g. CYP2B6). Three CYP gene families 
are mainly responsible for drug metabolism in humans and most other mammalian 
species i.e. CYP1, CYP2, and CYP3. CYP1 have two subfamilies CYP1A (i.e. CYP1A1 
and 1A2) and CYP1B. CYP1A1 is mainly extrahepatic while CYP1A2 is a hepatic 
enzyme. Both are induced by polycyclic aromatic hydrocarbons (PAR), found for 
example in cigarette smoke and charbroiled meat. CYP1A2 is involved in metabolism 
of several. CYP2 is the largest family of human CYPs identified to date. In addition, 
there is 92% nucleotide sequence similarity of CYP2B7P with CYP2B6.
1.2 In vitro models used to study drug biotransformation
Various methods are used to study the metabolic activity of a CYP enzyme in 
vitro including human liver microsomes, recombinant expressed CYPs, cytosol, 
S9 fraction, cell lines, transgenic cell lines, primary hepatocytes, liver slices, and 
perfused liver.
1.2.1 Human liver microsomes
Human liver microsomes are prepared from fresh or frozen liver tissue, and 
contain different proportions of all CYPs for each donor. Human liver microsomes 
contain membrane bound Phase I enzymes and Phase II enzymes such as CYPs and 
UDP glucuronosyltransferases.
1.2.2 Recombinant CYPs
Individual CYPs (including 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4, and 3A5) 
expressed in either lymphoblastoid cells or insect cells are available commercially from 
BD-Gentest Corporation [1].
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1.2.3 Primary hepatocytes
Hepatocytes represent a model for studying biotransformation and drug–drug 
interactions, such as inhibition and induction [2]. One disadvantage of using 
hepatocytes is that availability is limited. Once a fresh liver is obtained, the hepato-
cytes must immediately be plated, used for suspension studies, or cryopreserved for 
future studies [2].
1.2.4 Liver slices
Liver slices represent one of the earliest in vitro models for metabolism studies, 
dating back to the earlier part of the 20th century [3].
1.2.5 S9 fraction
The S9 fraction is the fraction of the liver cellscontaining both microsomes and 
cytosol. It is obtained by centrigation of whole-liver homogenate at 9000 X g [4].
1.2.6 Liver cell lines
Liver cell lines are less popular compared to other models. This is mainly due 
to their dedifferentiated cellular characteristics and incomplete expression of all 
families of metabolic enzymes [5].
1.2.7 Bupropion hydroxylation as a CYP2B6 index reaction
If a substrate is biotransformed to one of its metabolites via only one CYP, the 
pathway is called an index reaction. In this thesis work, conversion of bupropion to 
hydroxybupropion was used as an index reaction for CYP2B6 based on the evidence 
as follows. Bupropion is biotransformed to three main metabolites in vivo, including 
hydroxybupropion, threohydrobupropion, and erythrohydrobupropion. Bupropion 
is biotransformed to the active metabolite hydroxybupropion mainly via CYP2B6 in 
vitro [6].
1.3 Factors influencing interindividual variability in CYP2B6 function
On average, CYP2B6 accounts for approximately 1 to 6% of total CYP450 [7, 8]. 
It was estimated that interindividual variability accounts for a 50-fold difference in 
CYP2B6 enzyme content [9]. Although CYP2B6 expression is highly variable, it is 
found at substantial levels in a small percentage of the population [6, 8, 10]. In addition, 
CYP2B6*6B haplotype and alcohol use history were identified as significant predictors 
of bupropion hydroxylation. The CYP2B6*6B haplotype was present at an allele fre-
quency of 0.26. These correlations suggest that moderate alcohol consumption (at least 
14 drinks of alcohol per week) is associated with enhanced CYP2B6 gene transcription, 
but the presence of at least one CYP2B6*6B allele reduces this inductive effect.
1.3.1 Genetic polymorphism
Genetic variation in CYPs may affect the biotransformation of drugs metabo-
lized by those CYPs. Variation in a gene could arise from different causes. First, a 
single nucleotide polymorphism (SNP) is a single nucleotide variation in the genetic 
sequence. Another type of genetic variation is gene duplication in which a CYP gene 
is found in multiple copies.
Pharmacogenetics
4
1.3.2 Effect of SNPs on CYP2B6 in vitro
Various laboratories have attempted to correlate CYP2B6 genotype with CYP2B6 
phenotype in panels of human liver microsomes. Found novel point mutations in 
the CYP2B6 coding region: C64T, G516T, C777A, A785G and C1459T, at frequen-
cies of 5.3%, 28.6%, 0.5%, 32.6% and 14.0%, respectively [11]. Furthermore, our 
laboratory has studied the correlation between several SNPs in the CYP2B6 coding 
and promoter region (to −3000 base pairs (bp)) verses bupropion hydroxylation 
activity, CYP2B6protein levels, and CYP2B6 mRNA levels in vitro were measured in 
a bank of 54 human livers.
Initial analysis showed excellent correlation between bupropion hydroxylation 
activities and CYP2B6 protein content (Rs = 0.88) but relatively poor correlation 
between CYP2B6 protein levels and CYP2B6 mRNA levels (Rs = 0.44) (Figure 1A). 
We did not find any individual genotypesthat significantly correlated with bupro-
pion hydroxylation activity, CYP2B6 protein or mRNA levels, but found that alcohol 
use history and the CYP2B6*6B haplotype (−1456 t > c, −750 t > c, G516T, A785G 
[Q172H, K262R], p = 0.011) were significant predictors of bupropion hydroxylation 
(Figure 1B). The CYP2B6*6B haplotype was present at a frequency of 0.26 [10].
Jinno et al. [12] expressed CYP2B6 mutants (CYP2B6.2,.3,.4,.5,.6, and 7) in 
COS-1 cells and found that compared to wild type, CYP2B6.6 (G516T, A785G 
[Q172H, K262R]) was expressed at a lower protein level, but had significantly 
higher Km and Vmax values for activity of 7-ethoxy-4-trifluoromethylcoumarinO-
deethylation (Figure 1C). Lang et al. identified four novel CYP2B6 alleles as 
phenotypic null alleles [13].
1.3.3 Effect of SNPs in vivo
When compared single-dose bupropion pharmacokinetics in 121 healthy male 
German Caucasian volunteers and found a correlation between the presence of the 
*4 allele (A785G [K262R]) and a higher (1.7-fold) bupropion clearance, although 
only a minor fraction of the variability in bupropion and hydroxybupropion kinetics 
could be explained by this variant [14]. Supporting our in vitro results, a clinical study 
involving efavirenz found that the CYP2B6*6 (G516T, A785G [Q172H, K262R]) geno-
type correlated with high plasma efavirenz concentrations in HIV-patients treated 
with standard efavirenz-containing regimens [15].
1.3.4 Ethnic differences in CYP2B6 SNPs
There are ethnic differences in the frequencies of CYP2B6 genotypes that 
could account for race/ethnic differences in CYP2B6 phenotype. For example, 89 
Caucasians and 50 African-Americans who were receiving efavirenz treatment were 
genotyped for G516T [Q172H] [16].
1.3.5 CYP2B6 inducers
Various CYP2B6 inducers have been identified, including carbamazepine, 
phenobarbital and related barbiturates, and rifampin [17, 18].
1.4 Mechanisms of CYP induction
Post-transcriptional mechanisms include both mRNA and protein stabilization 
that may be mediated through transacting regulators or through changes in the 
phosphorylation status of the enzyme.
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1.4.1 Transcriptional regulation
In addition to the induction of CYP1A genes, at least three other nuclear receptors 
(NRs) can induce transcription of drug metabolizing enzymes. These are the consti-
tutive androstane receptor (CAR), the pregnane X receptor (PXR), and the peroxi-
some proliferator-activated receptor (PPAR).
Figure 1. 
Data from our laboratory [10] showing relationships between CYP2B6 activities, protein content and mRNA 
content measured in a bank of 54 human livers (A); as well as effects of alcohol and *6B allele on CYP2B6 
activity (B). A study by [12] showed that some CYP2B6 amino acid coding variants expressed in COS-1 cells 




Post-transcriptional regulation mechanisms include both mRNA and protein sta-
bilization as well as stimulated of mRNA and protein degradation. These processes can 
result in an increase or decrease of enzyme expression, respectively. A good example 
is CYP2E1 that is regulated by several post-transcriptional mechanisms [19, 20].
1.5 Messenger RNA splicing
As seen in Figure 2, splicing is the process that results in excision of the introns 
from a pre-mRNA and the joining of the resultant exons. The splicing process is 
directed by special sequences at the intron/exon junctions called splice sites. The 5′ 
splice site marks the exon/intron junction at the 5′ end of the intron. This includes 
a GU dinucleotide at the intron end encompassed within a larger, less conserved 
consensus sequence. At the other end of theintron, the 3′ splice site region has three 
conserved sequence elements: the branch point, followed by a polypyrimidine tract, 
followed by a terminal AG at the extreme 3′ end of the intron. Splicing is carried 
out by the spliceosome, a large macromolecular complex that assembles onto these 
sequences and catalyzes the two transesterification steps of the splicing reaction. 
Splicing activators are generally thought to interact with components of the spli-
ceosome to stabilize their binding to adjacent splice sites. SR (splicing regulator) 
proteins bind to exonic splicing enhancer elements or intronic enhancer elements to 
stimulate U2AF binding to the upstream 3− splice site, or U1 snRNP binding to the 
downstream 5′ splice site (Figure 2B).
1.5.1 Alternative mRNA splicing
Alternative pre-mRNA splicing is a central mode of genetic regulation in higher 
eukaryotes (Figure 3). Alternative splicingplays an extremely important role in 
expanding protein diversityand might therefore partially explain the apparent 
Figure 2. 
Molecular mechanisms involved in mRNA splicing. (A) Splicing takes place in two transesterification steps. The 
first step results in two reaction intermediates: the detached 5′- exon and an intron/3′-exon fragment in a lariat 
structure. The second step ligates the two exons and releases the intron lariat. (B) The complex can be converted 
into the active spliceosome and involves the recognition of the 5′ splice site by U1 snRNP and the branch-point 
sequence and 3′ splice site by SF1 and U2AF, respectively with the aid of SR proteins.
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discrepancybetween gene number and organism complexity [21]. Approximately 
40–60% of human genes are estimatedto have distinct splice variants [22]. The 
regulation of alternative splicing can involve on/off regulationof the products of 
particular genes and the production of alternativeproducts with clearly separable 
functions, often in a cell-type-specificmanner [23].
1.5.2 Regulation of splicing: SRproteins and regulatory elements
The SR proteins constitute the best-studied family of splicing regulators. The 
SR proteins have a common domain structure of one or two RNP-cs RNA binding 
domains followed by what is called an RS domain containing repeated arginine/
serine dipeptides.
The RNA regulatory elements are enhancers or suppressors, diverse in sequence, 
and often embedded within nucleotides that also code for protein (exonic splice 
enhancers), but also found in introns. In the intron, the IEs and ISs are often found 
within a polypyrimidine tract or immediately adjacent to the branch point or 5′ 
splice site.
However, splicing regulatory elements can also act from a distance, being found 
hundreds of nucleotides away from the regulated exon.
SR proteins and exonic splicing enhancers (ESEs) play an important role in the 
regulation of alternative splicing. An SR protein binds to an ESE through its RNA-
recognition motifs (RRM) and contacts the components of a spliceosome through 
its RS domain. Errors in splicing regulation have been implicated in a number of 
different disease states.
1.6 Effect of alcohol on CYP genes
A Chronic exposure to alcohol produces change in gene expression and alcohol-
ics suffer long-term dysfunction in multiple organ systems, including the liver, 
immune system and heart [24]. Alcohol is likely to be involved in a significant 
number of adverse drug reactions.
Figure 3. 
Patterns of alternative splicing variation. Putative splice variants were classified according to the basic patterns 
of alternative splicing. (A) Cassette exon: an exon is spliced out with neighboring introns or included in the 
mature mRNA. (B) Internal donor site: competing donor (5′) splice sites exist for one acceptor site within an 
intron. (C) Internal acceptor site: competing acceptor (3′) splice sites exist for one donor site within an intron. 
(D) Retained intron: an intron is spliced out or included in RNA [20].
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1.6.1 Inductive effects of ethanol in vitro
Alcohol has been shown to induce hepatic drug metabolism [25].
If administered after a chronic period of alcohol consumption, drugs that 
are metabolized by enzymes induced by alcohol may have significantly altered 
biotransformation.
It is found that incubation with ethanol and isopentanol resulted in a synergistic 
induction of CYP2B1/2 activity and protein levels in cultured rat hepatocytes; and 
an additive to synergistic induction of CYP2H1/2 activity and protein levels in 
cultured chick hepatocytes [26].
1.6.2 Inductive effects of ethanol in animals in vivo
It is well established that CYP2E1 is induced by alcohol in humans. In vitro 
and in vivo human clinical studies have shown that CYP2E1 is induced by ethanol 
[27–29]. The metabolic ratio of CYP2E1 activity was higher in a group of volunteers 
that were drinking at least 80 grams of ethanol per day for at least 5 years compared 
to abstaining alcoholics (for 14 days) and nonalcoholics with liver disease.
In a study subjects drank 40 grams of red wine for a total of four weeks and the 
metabolic ratio of CYP2E1 activity increased starting after one week of drinking, 
indicating increased CYP2E1 activity [28]. The ratio continuously increased when 
measured each week throughout the four-week study.
Brain samples from smoking alcoholics compared to nonsmoking, nondrinking 
subjects showed increased CYP2B6 protein expression as determined by western 
blot analysis. In Chapter 3 we use human hepatic and intestinal cell lines to deter-
mine whether ethanol can induce CYP2B6 and CYP2B7 mRNA expression; and also 
explore a role for the nuclear receptor CAR and/or PXR in this induction.
1.6.3 Inhibiting effects of ethanol in vitro
In vitro, concentrations of ethanol (0.1–3%) had inhibitory effects on CYPs 
1A1, 1A2, 2A6, 2B6, 2C8, 2C19, 2D6, and 3A4. In human liver microsomes, ethanol 
inhibits the biotransformation of CYP3A substrates nifedipine, triazolam, and 
testosterone [30].
1.6.4 Inhibiting effects of ethanol in vivo
There is evidence that an acute dose of alcohol inhibits some human CYPs in 
vivo. In vitro data may explain the observations that acute ethanol intoxication 
potentiates the action of barbiturates, while there is increased resistance to the 
action of some sedatives in sober alcoholics. Ethanol does not appear to inhibit 
CYP2B6 in vivo in humans since it did not alter pharmacokinetics of bupropion 
when acutely coadministered with bupropion [31].
1.7 CYP pseudogenes
Pseudogenes are disabled copies of genes that do not produce a functional, full-
length copy of a protein. They are of two main types of pseudogenes. Firstly, there 
are processed pseudogenes. Secondly, there are nonprocessed pseudogenes [32, 33]. 
With subsequent evolutionary time (generations), these pseudogenes accumulate 
further coding and noncoding disablements. There are other types of protein-
related pseudogenes that are not accounted for in the above classification including 
semiprocessed pseudogenes.
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The extent of the pseudogene population in the human genome is not yet clear. 
It has been estimated that thereare ~9000 processed and ~ 10,000 nonprocessed 
pseudogenesin the human genome; [34, 35]. A review of available genomic infor-
mation indicates that there are many pseudogenes in the CYP family, and it has 
estimated that there may be more CYP pseudogenes than functional genes within 
the drug metabolizing enzyme families – CYP 1, 2 and 3 (see Table 1). A focus of 
the studies described in Chapter 4 of this dissertation is CYP2B7P. CYP2B7P has 
been identified as a pseudogene due to the presence of a single nucleotide change 
resulting in a premature stop codon in exon 7 (X378) and predicted truncated 
protein [36].
CYPs Function Genes/pseudogenes
CYP1 drug metabolism (3 subfamilies 3 genes 1 pseudogene).
CYP2 drug and steroid metabolism (13 subfamilies 16 genes 16 pseudogenes).
CYP3 drug metabolism (1 subfamily 4 genes 2 pseudogenes).
CYP4 arachidonic acid or fatty acid 
metabolism
(5 subfamilies 11 genes 10 pseudogenes).
CYP5 thromboxane A2 synthase (1 subfamily 1gene).
CYP7A bile acid biosynthesis 7-alpha 
hydroxylase of steroid nucleus
(1 subfamily member).
CYP7B brain specific form of 7-alpha 
hydroxylase
(1 subfamily member)
CYP8A prostacyclin synthase (1 subfamily member).
CYP8B bile acid biosynthesis (1 subfamily member).
CYP11 steroid biosynthesis (2 subfamilies 3 genes).
CYP17 steroid biosynthesis 17-alpha 
hydroxylase
(1 subfamily 1 gene).
CYP19 steroid biosynthesis aromatase 
forms estrogen
(1 subfamily 1 gene).
CYP20 Unknown function (1 subfamily 1 gene).
CYP21 steroid biosynthesis (1 subfamily 1 gene 1 pseudogene).
CYP24 vitamin D degradation (1 subfamily 1 gene).
CYP26A retinoic acid hydroxylase (1 subfamily member).
CYP26B probable retinoic acid hydroxylase (1 subfamily member).
CYP26C probabvle retinoic acid hydroxylase (1 subfamily member).
CYP27A bile acid biosynthesis (1 subfamily member).
CYP27B vitamin D3 1-alpha hydroxylase 
activates vitamin D3 (1 subfamily 
member).
CYP27C unknown function (1 subfamily member).
CYP39 7 alpha hydroxylation of 24 
hydroxy cholesterol
(1 subfamily member).
CYP46 cholesterol 24-hydroxylase (1 subfamily member).
CYP51 cholesterol biosynthesis lanosterol 
14-alpha demethylase
(1 subfamily 1 gene 3 pseudogenes).
Table 1. 
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In Chapter 4 we determine whether CYP2B7P is a polymorphic gene in humans, 
and whether there are genetic variants that code for a full length CYP2B7 protein, 
lacking the common stop codon (X378). We also evaluate whether the recombinant 
full-length variant CYP2B7 (R378) is capable of hydroxylating the CYP2B6 substrate 
bupropion.
2. Conclusion
The main objective of the work described in this thesis dissertation was to 
study the role of genetic and environmental factors in determining interindividual 
variability of the CYP2B subfamily.
The results of these studies identify certain CYP2B6 genetic polymorphisms, 
mRNA splicing variants, and alcohol ingestion as significant factors that determine 
interindividual variability of CYP2B-mediated oxidation of drugs in people.
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